Hana, NovaDel to submit new version of Zensana

Hana Biosciences and NovaDel Pharma have decided to file a different formulation of Zensana with the FDA after running into manufacturing problems with the therapy recently. A European version of Zensana, an oral spray designed to treat the side effects of cancer treatments, will be submitted to the FDA next year. In addition, Hana announced that it was dropping its bid for a Special Protocol Assessment for Marqibo following the FDA's decision to limit SPA's to randomized trials. Hana's shares fell about 20 percent in premarket trading.

- check out the press release for more
- here's the AP report on the regulatory moves

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.